Fifty-two previously untreated patients with small-cell lung carcinoma (SCLC) were treated
with a combination of carboplatin 300 mg/m2 intravenously (IV) on day 1 and etoposide 100 …

Forty-seven untreated patients with small-cell lung cancer (SCLC) were treated with a
combination of etoposide (170 mg/m 2 intravenously, iv, days 3–5) and cisplatin (50 mg/m 2 …

Thirty-two previously untreated, fit patients with small-cell lung carcinoma (SCLC) were
treated with an intensive combination chemotherapy regimen, with the aim of prolonging …

The efficacy and toxicity of carboplatin 100 mg/m2, administered intravenously (IV) daily X 3,
and VP-16-213 120 mg/m2, IV daily X 3, administered every 28 days for six courses, was …

Forty‐seven consecutive patients with small cell lung cancer (SCLC) were treated with a
combination chemotherapy program including 60 mg/m2 of cisplatin (P) on day 1 and 120 …

Fourteen previously untreated patients with metastatic small cell lung carcinoma (SCLC)
were treated with carboplatin, 400 mg/m2, given as a 1-hour infusion every 28 days. Eleven …

Small-cell lung cancer (SCLC) is a disseminated disease regardless of our ability to
document all sites. Chemotherapy is thus the cornerstone of treatment. There are multiple …

Lung cancer is the leading cause of death due to cancer in the United States, and
approximately 178,100 new cases were estimated to occur last year. Small-cell lung cancer …

Because of potential synergistic interactions, we added 25 mg/m 2 iv cisplatin (P) 25 given
on days 1–5 to the combination of 45 mg/m 2 iv doxorubicin (A) given on day 1, 800 mg/m 2 …

Carboplatin, a cisplatin analogue without significant nephrotoxicity, was used as a single
agent in the treatment of 56 patients with small cell lung carcinoma at a dose of 300–400 …